These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18536236)

  • 21. Pathobiology of HBV mutants and clinical impact for treatment monitoring.
    Si Ahmed SN; Zoulim F
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):309-20. PubMed ID: 19344244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term entecavir therapy of chronic severe hepatitis B.
    Chen J; Han JH; Liu C; Yu RH; Li FZ; Li QF; Gong GZ
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):261-6. PubMed ID: 19502165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.
    Yim HJ; Lok AS
    Hepatology; 2006 Feb; 43(2 Suppl 1):S173-81. PubMed ID: 16447285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
    J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of quantitative hepatitis B virus DNA levels in serum and liver biopsy samples of chronic hepatitis B patients].
    Rüzgar M; Cetin Akhan S; Vahaboğlu H
    Mikrobiyol Bul; 2008 Apr; 42(2):283-91. PubMed ID: 18697426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.
    Madan K; Batra Y; Jha JK; Kumar S; Kalra N; Paul SB; Singh R; Duttagupta S; Panda SK; Acharya SK
    Trop Gastroenterol; 2008; 29(2):84-90. PubMed ID: 18972767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients.
    Lu L; Zhang HY; Yueng YH; Cheung KF; Luk JM; Wang FS; Lau GK
    J Viral Hepat; 2009 Feb; 16(2):104-12. PubMed ID: 19175882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment.
    Feld JJ; Heathcote EJ
    Semin Liver Dis; 2006 May; 26(2):116-29. PubMed ID: 16673290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term therapy with nucleoside analog entecavir (baraclude) in patients with chronic hepatitis B].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2011; 65(2):313-7. PubMed ID: 21913482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.
    Chevaliez S; Pawlotsky JM
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1031-48. PubMed ID: 19187865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decline of serum HBV DNA and no change apportioned by the same hepatic parenchyma cell volume from hepatic fibrosis stage 1 to stage 4 during the natural history of chronic hepatitis B.
    Ke WM; Xie SB; Yu LN; Liu T; Lai J; He DQ; Li XH; Gao ZL; Ke Y; Chen PJ
    Intervirology; 2008; 51(4):235-40. PubMed ID: 18812696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Halting the natural history of hepatitis B viral infection: a paradigm shift.
    Perrillo RP; Jacobson IM
    Semin Liver Dis; 2007 Aug; 27 Suppl 1():3-8. PubMed ID: 17701844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic strategies for chronic hepatitis B virus infection in 2008.
    Khokhar A; Afdhal NH
    Am J Med; 2008 Dec; 121(12 Suppl):S33-44. PubMed ID: 19185073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of acute hepatitis B and reactivation of hepatitis B.
    Jindal A; Kumar M; Sarin SK
    Liver Int; 2013 Feb; 33 Suppl 1():164-75. PubMed ID: 23286861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chronic hepatitis B.
    Loomba R; Liang TJ
    Antivir Ther; 2007; 12 Suppl 3():H33-41. PubMed ID: 18284181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
    Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
    Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indications for therapy in hepatitis B.
    Degertekin B; Lok AS
    Hepatology; 2009 May; 49(5 Suppl):S129-37. PubMed ID: 19399799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus-related cirrhosis: natural history and treatment.
    Chu CM; Liaw YF
    Semin Liver Dis; 2006 May; 26(2):142-52. PubMed ID: 16673292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.